Previous Statements by MYL
» Mylan's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
The company had a mixed fourth quarter.
GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.